Skip to content

Clinical trials

Phase 1/2 Hereditary Sensory and Autonomic Neuropathies trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Hereditary Sensory and Autonomic Neuropathies Phase: Phase 1/2 Country / region: United States Clear all

22 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20072
20103
20121
20132
20161
20171
20201
20213
20221
20232
20241
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed10
Recruiting7
Terminated2
Active, not recruiting1
Suspended1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Children's Hospital Medical Center, Cincinnati3
Cascadian Therapeutics Inc.2
Novartis Pharmaceuticals2
Acrivon Therapeutics1
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)1
Artios Pharma Ltd1
Arvinas Inc.1
Curis, Inc.1
David Bajor, MD1
EMD Serono Research & Development Institute, Inc.1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hereditary Sensory and Autonomic Neuropathies22
Colorectal Neoplasms5
Squamous Cell Carcinoma of Head and Neck5
Breast Neoplasms4
Carcinoma, Non-Small-Cell Lung4
Ovarian Neoplasms4
Recurrence4
Endometrial Neoplasms3
Head and Neck Neoplasms3
Tuberous Sclerosis3

Trials

Showing 1 to 22 of 22. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.